Properties
What is it?
Composition: Active substance: epinephrine; 1ml of solution contains 1.8mg of epinephrine hydro-tartrate (adrenaline tartrate); Excipients: sodium metabisulfite (E 223), sodium chloride, water for injection. Indications: Emergency allergic reactions: anaphylactic shock developing after administration of medicinal products, sera or contact with allergens; relief of bronchial asthma attacks; asystole, cardiac arrest; potentiation of local anesthetics; acute developing AV-blockade grade III. Contraindications: Hypersensitivity to the ingredients of the preparation; hypertrophic obstructive cardiomyopathy; severe aortic stenosis; tachyarrhythmias; ventricular fibrillation; pheochromocytoma; angle-closure glaucoma; shock (except anaphylactic); general anesthesia with inhalation agents: fluorotane, cyclopropane, chloroform; second stage of labor; use on fingers of hands, lower extremities, nose, parts of genitals. Dosage and administration: The medicinal product is administered subcutaneously, intramuscularly, sometimes intravenously or intravenously dropwise. Adults: Anaphylactic shock: The medicinal product is administered slowly intravenously at a dose of 0.5ml diluted (a single dose is diluted in 20ml of 40% glucose solution). Subsequently, if necessary, continue intravenous dropwise administration at a rate of 1mcg/min, for which 1ml of adrenaline is diluted in 400ml of 0.9% sodium chloride solution or 5% glucose. If the patient's condition allows, it is more advisable to administer intramuscularly or subcutaneously 0.3-0.5ml of the medicinal product diluted or undiluted. Bronchial asthma: The medicinal product is administered subcutaneously at a dose of 0.3-0.5ml diluted or undiluted. If repeated administration is necessary, this dose can be administered every 20 minutes (up to 3 times). Intravenous administration of 0.3-0.5ml of the medicinal product diluted is also possible (dissolve a single dose in 20ml of 40% glucose solution). As a vasoconstrictor: The medicinal product is administered intravenously dropwise at a rate of 1mcg/min (with possible increase to 2-10mcg/min). Asystole: Administer the medicinal product intracardially at a dose of 0.5ml, diluted (dissolve a single dose in 10ml of 0.9% sodium chloride solution). Resuscitation measures (cardiac arrest, acute developing AV-blockade grade III): The medicinal product is administered slowly intravenously at 1ml every 3-5 minutes diluted. Prolonged action of local anesthetics: The medicinal product is administered at a concentration of 1:50000-1:100000. Dosage depends on the type. Children: Asystole in newborns: The medicinal product is administered slowly intravenously at a dose of 10-30mcg/kg body weight every 3-5 minutes. Anaphylactic shock: The medicinal product is administered subcutaneously or intramuscularly at a dose of 10mcg/kg body weight (maximum - up to 0.3mg). If necessary, administration is repeated every 15 minutes (up to 3 times). Bronchospasm: The medicinal product is administered subcutaneously at a dose of 10mcg/kg body weight (maximum - up to 0.3mg). If necessary, administration is repeated every 15 minutes (up to 3-4 times) or every 4 hours. Children: The medicinal product can be used in children
